Key points are not available for this paper at this time.
Malignancy is a long-term complication of lung transplantation (LTx); however, contemporary Australian data and detailed evaluation of nonreportable cancers are lacking. Retrospective review of LTx recipients' medical records and registry data linkage were performed to identify histologically proven malignancies. Baseline clinico-demographic variables were collected, and cancer incidence was compared with reported data for the general Australian population. There were 1,715 LTx in 1,631 patients between 1989 and 2021, with a follow-up of 9,696 person-years. Eight hundred and ninety-three (54.8%) patients were male, and the median age at first LTx was 54.7 years. There were 886 deaths with a median overall survival of 7.5 years (95% confidence intervals (CI) 6.8-8.3 years). One thousand seven hundred and seventy-four separate invasive cancer events occurred across 407 patients, of which, 1,588 (89.5%) were nonmelanoma skin cancers (NMSCs). This translated to a 9-fold increased incidence of NMSCs and a 4-fold increased incidence of other cancers compared with the general population. Cancer mortality reached parity with chronic lung allograft dysfunction 10 years postfirst transplant and was independently associated with age (hazard ratios (HR) per year increase in age 1.02 95% CI 1.01-1.03, p = 0.001), Epstein-Barr virus primary mismatch (HR 3.24 95% CI 1.68-6.25, vs nonmismatch, p = 0.002), and cancer count (HR per cancer event 1.19 95% CI 1.13-1.24, p < 0.0001), but was not associated with a pretransplant malignancy history. Our 31-year single-center experience demonstrates that malignancies are a significant mortality burden to long-term LTx survivors, dominated by NMSCs that are poorly reported in cancer datasets. A history of pretransplant malignancy was associated with a shorter time to post-transplant malignancy but was not associated with cancer death.
Yeoh et al. (Thu,) studied this question.